Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;8(9):1250-8.
doi: 10.4161/hv.20579. Epub 2012 Aug 6.

The detailed analysis of the changes of murine dendritic cells (DCs) induced by thymic peptide: pidotimod(PTD)

Xiaofang Hu  1 , Wei Zhang, Lu Wang, Nan Wan, Bing Wang, Weiwei Li, Hui Hua, Xu Hu, Fengping Shan
Affiliations

The detailed analysis of the changes of murine dendritic cells (DCs) induced by thymic peptide: pidotimod(PTD)

Xiaofang Hu et al. Hum Vaccin Immunother. 2012 Sep.

Abstract

The aim of present research is to analyze the detailed changes of dendritic cells (DCs) induced by pidotimod(PTD). These impacts on DCs of both bone marrow derived DCs and established DC2.4 cell line were assessed with use of conventional scanning electron microscopy (SEM), flow cytometry (FCM), transmission electron microscopy (TEM), cytochemistry assay FITC-dextran, bio-assay and enzyme linked immunosorbent assay (ELISA). We demonstrated the ability of PTD to induce DC phynotypic and functional maturation as evidenced by higher expression of key surface molecules such as MHC II, CD80 and CD86. The functional tests proved the downregulation of ACP inside the DCs, occurred when phagocytosis of DCs decreased, with simultaneously antigen presentation increased toward maturation. Finally, PTD also stimulated production of more cytokine IL-12 and less TNF-α. Therefore it is concluded that PTD can markedly exert positive induction to murine DCs.

PubMed Disclaimer

Figures

None
Figure 2. The curve of the DCs’ proliferation after treatment with a range of concentrations of PTD for 48h determined by method of MTS.
None
Figure 3. Morphology of the BMDCs before and after treatment with PTD under a light microscope (A) ( × 400). The images of DC2.4 cells before and after treatment with PTD with SEM (B) ( × 3500).
None
Figure 4. TEM for changes of lysosomes inside the DCs2.4 cells before and after treatment with PTD.
None
Figure 5. The ACP activity of the DCs2.4 cells after treatment with 800 ug/ml PTD for 48 h.
None
Figure 6. Confirmation by FCM of the DCs2.4 cells’ phagocytic effect. Results represent the mean ± SD of three independent samples.
None
Figure 7. Immunohistochemical staining of DCs2.4 cells after treatment with PTD.
None
Figure 8. Upregulation of key surface molecules on BMDCs (A) and DCs2.4 cells (B) after treatment with PTD for 48 h. The cells were respectively collected and stained with mAbs to CD40, CD86, and MHCII. Expression of surface markers was analyzed by FCM, which was displayed respectively by the single parameter diagrams. The values shown in the proðles were the gated % and the mean ñuorescence intensity indexes (MFI). Results represent the mean ± SD of three independent samples.
None
Figure 9. (A, B) The production of IL-12p70, IL-12p40 by the DCs 2.4 cells after treatment with PTD. The histograms above showed the IL-12p70, IL-12p40 production levels after PTD stimulation. Results represent the mean ± SD of three independent samples. (C) The production of TNF-α by the DCs 2.4 cells after treatment with PTD. Results represent the mean ± SD of three independent samples.
None
Figure 1. The CD11c+ cell puriðcation with MACS. After co-culture for 6 d, the purity of CD11c+ cells were examined and the percentage were over 80%. Followed by purification with MACS, the CD11c+ cells were enriched and the results of FCM showed that the purity CD11c+ cells approached 95%.
See this image and copyright information in PMC

References

    1. de la Torre González C, Pacheco Ríos A, Escalante Domínguez AJ, del Río Navarro BE. [Comparative meta-analysis of immunoestimulant agents used in pediatric patients in Mexico] Rev Alerg Mex. 2005;52:25–38. - PubMed
    1. Riboldi P, Gerosa M, Meroni PL. Pidotimod: a reappraisal. Int J Immunopathol Pharmacol. 2009;22(2):255-62. immunosuppression. Arch Pharm Res. 2008;31:1153–9. - PubMed
    1. Riboldi P, Gerosa M, Meroni PL. Pidotimod: a reappraisal. Int J Immunopathol Pharmacol. 2009;22:255–62. - PubMed
    1. Du Xiao F, Jiang CZ, Wu CF, Won EK, Choung SY. Synergistic immunostimulatory effect of pidotimod and red ginseng acidic polysaccharide on humoral immunity of immunosuppressed mice. Pharmazie. 2008;63:904–8. - PubMed
    1. Zervoudis S, Iatrakis G, Peitsidis P, Peitsidou A, Papandonopolos L, Nikolopoulou MK, et al. Complementary treatment with oral pidotimod plus vitamin C after laser vaporization for female genital warts: a prospective study. J Med Life. 2010;3:286–8. - PMC - PubMed

Publication types

MeSH terms